Organoid Science (CEO Jongman Yoo), an innovative organoid-based regenerative therapy and new drug development company, announced on the 15th that it has selected Korea Investment & Securities as the underwriter for the listing in order to promote an initial public offering (IPO) in 2023.
We plan to conduct Pre-IPO (investment attraction before initial public offering) and technology evaluation in early 2023 and submit a preliminary review request for listing in the second half of 2023.
Organoid Science is an innovative company specializing in organoids and was founded in 2018 by CEO Jongman Yoo, a former doctor at Cha Medical School and head of the Organoid Research Center.
The main pipeline, organoid-based regenerative therapy, is an innovative technology that not only provides simple pain relief but also regenerates damaged organs by transplanting them directly to the lesion site, and is currently on the verge of entering clinical trials. We expect to pioneer and lead the market for incurable diseases for which there is currently no fundamental treatment.
In addition to ATORM, a regenerative treatment platform, we have commercialized ‘ADIO’, an organoid-based new drug evaluation platform, and established it as a drug efficacy evaluation service, contributing to increasing the efficiency and success rate of new drug development for new drug development companies.
Organoid Science CFO (Chief Financial Officer) Hong Jin-man said, “We plan to enter the clinical trial of ATORM-based regenerative therapy this year and generate meaningful sales in the ADIO business field, and accelerate preparations for listing, starting with technology evaluation in 2023, as planned.” reported.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2022’ news